Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ACMG/AMP Variant ClassifierAmsterdam Criteria IICYP2C19 Phenotype InterpreterDLCN Score (FH)GJB2 Variant InterpreterGhent-2 Criteria (Marfan)HTT CAG Repeat (Huntington)Hereditary Thrombophilia VTE RiskRevised Bethesda GuidelinesTyrer-Cuzick Breast Risk
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

Revised Bethesda Guidelines

Revised Bethesda Guidelines — Lynch Syndrome

Any ONE criterion met = indication to test CRC tumour for MSI and MMR-IHC. More sensitive than Amsterdam Criteria. Applies to patients with established or suspected CRC diagnosis.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

When to Use

Selecting CRC tumours for MSI (Microsatellite Instability) and/or MMR-IHC testing to identify Lynch syndrome candidates.
Applicable to patients with newly diagnosed or confirmed colorectal cancer at any age.
More sensitive than Amsterdam Criteria for Lynch syndrome identification — any one trigger criterion is sufficient.
Endorsed by NCI, ASCO, NCCN, and ESMO as clinical screening criteria for Lynch syndrome.

Strategy Note

Many centres now use universal reflex MMR-IHC/MSI testing of ALL colorectal (and endometrial) cancers regardless of Bethesda criteria — this has replaced Bethesda as the frontline strategy in progressive healthcare systems.

Last Comprehensive Review: 2026